Recent news on Ifosfamide

ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR  -  Apr 16, 2007
PharmaLive.com (press release),Data presented demonstrated oral availability of ZIO-201 and activity in a variety of cancer models, including those with ifosfamide (IFOS) and

Data For Orally Active Form Of ZIO-201 Shows Oral Availability Of ...  -  Apr 16, 2007
Trading Markets,According to Barbara Wallner, Chief Technical Officer at ZIOPHARM: "Ifosfamide has been tested as an oral drug but it is problematic at effective doses

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial ...  -  Apr 12, 2007
Medical News Today (press release),Doxorubicin and ifosfamide are the most commonly used chemotherapeutic agents in patients with advanced soft tissue sarcoma, but response rates are low and

Pro-Pharmaceuticals Collaborates with Chemwerth to Scale-up ...  -  Feb 20, 2007
PharmaLive.com (press release),Etoposide USP, Fludarabine Phosphate, Gemcitabine HCl USP, Ifosfamide USP, Irinotecan HCl 3H2O, Mitoxantrone HCl USP/PhEur and Thiotepa USP.

Ziopharm Adds $31M For Clinical Oncology Pipeline  -  Feb 16, 2007
BioWorld Online,Ziopharm also expects to start a pivotal trial this year with ZIO-201, a metabolite of ifosfamide, in advanced sarcoma. That product is finishing up Phase

Camptosar® Evaluated in Children with Relapsed or Refractory ...  -  Feb 14, 2007
Cancer Consultants (press release),Active agents for the treatment of recurrent or refractory rhabdomyosarcoma include Cytoxan® (cyclophosphamide), Ifex® (ifosfamide),

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial ...  -  Feb 6, 2007
PharmaLive.com (press release),...variety of single agent and combination regimens including topotecan, cyclophosphamide, doxorubicin, vincristine, irinotecan, ifosfamide and cisplatin.

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial ...  -  Feb 5, 2007
PR Newswire (press release),...irinotecan, ifosfamide and cisplatin. Phase 2 Clinical Trial Design Approximately 50 patients with extensive recurrent sensitive small cell lung cancer,

Dose-Intensive Chemotherapy with Stem Cell and Neupogen® Support ...  -  Feb 5, 2007
Cancer Consultants (press release),A randomized phase III study that intensified doses of ICE (ifosfamide, carboplatin, and etoposide) administered with autologous stem cell and Neupogen

Dose-intensive Chemotherapy Improves Survival for Patients with ...  -  Feb 2, 2007
Cancer Consultants (press release),According to an article recently published in the Journal of Thoracic Oncology, intensified doses of the chemotherapy regimen referred to as ICE (ifosfamide

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial ...  -  Jan 30, 2007
PipelineReview.com (press release),...including topotecan, anthracyclines such as doxorubicin, gemcitabine, cyclophosphamide, vinorelbine, hexamethylmelamine, ifosfamide, and etoposide.

ZIO-201 Preclinical Data Demonstrate Effectiveness in Pediatric ...  Nov 2, 2006
Cyclophosphamide and the related drug ifosfamide are widely used alkylating agents for treating a number of cancers including sarcoma. ... -Genetic Engineering News (press release), ZIOPHARM Presents ZIO-201 Phase I Data at CTOS  Nov 3, 2006
ZIO-201 is a proprietary form of the therapeutic active metabolite of ifosfamide (IFOS), a drug that is the standard of care in the treatment of sarcoma and is ... -Business Wire (press release), ZIOPHARM Presents Updated Clinical Data On ZIO-201 At CTOS Meeting ...  Nov 3, 2006
ZIO-201 is a proprietary form of the therapeutic active metabolite of ifosfamide or IFOS, a drug that is the standard of care in the treatment of sarcoma and ... -Trading Markets, Healthy look belies desperation  Oct 29, 2006
Pain, from the chemotherapy drug, Ifosfamide, that sent her body into allergic reactions, then another, Adriamycin, which stripped her of her hair, added weight ... -Daytona Beach News-Journal, ZIOPHARM ZIO-201 Featured on ABC News  Aug 8, 2006
ZIO-201, the Company's proprietary alkylating drug, is the active metabolite of ifosfamide and, unlike ifosfamide, does not produce the other metabolites ... -Genetic Engineering News

Metastatic Alveolar Soft Part Sarcoma of the Breast  Jun 23, 2006
...part sarcoma was made. She was given 3 courses of chemotherapy with vincristine, ifosfamide, and cisplatin. Seven months after chemotherapy ... -Journal of Ultrasound in Medicine (subscription)



Chemotherapy Combination Produces Promising Results in Ewing’s ...  Apr 5, 2006
Among patients with high-risk Ewing’s sarcoma family of tumors (ESFT), treatment with an intensified chemotherapy regimen of ifosfamide, carboplatin, and ... - Cancer Consultants

Taxotere® plus Gemzar® is an Effective Regimen for Advanced Soft ...  Apr 4, 2006
The most frequently used drugs are the anthracyclines such as Adriamycin® (doxorubicin) and alkylating agents such as Ifex® (ifosfamide) and dacarbazine ... - Cancer Consultants

First patient treated in phase 1/2 trial with alkylating drug in ...  Mar 28, 2006
ZIO-201 (isophosphoramide mustard or IPM) is the active metabolite of ifosfamide, a frequently used treatment for sarcoma. Due to ... - Therapeutics Daily (subscription)

ZIOPHARM Presents ZIO-201/202/203 Preclinical Data at AACR; Anti ...  Apr 3, 2006
Southern Research Institute. ZIO-201 is the Company's proprietary alkylating drug and the active metabolite of ifosfamide. It is ... - PharmaLive.com

Ziopharm presents preclinical kidney toxicity data on metabolite ...  Mar 23, 2006
Ziopharm Oncology, Inc. (ZIOP) presented preclinical data showing ZIO-201, the active metabolite of ifosfamide, may be less likely to kill normal kidney cells ... - Therapeutics Daily (subscription)

ICE Plus CAV Intensification Promising for High Risk Ewing’s ...  Mar 31, 2006
Researchers from Italy have reported that an induction regimen of ifosfamide, carboplatin and etoposide (ICE) followed by intensification with cyclophosphamide ... - Cancer Consultants

Updated Guidelines for Treatment of Ovarian Cancer  Mar 27, 2006
...recurrent ovarian cancer was broadened to include Arimidex® (anastrozole), Avastin® (bevacizumab), Camptosar® (ironotecan), Ifex® (ifosfamide), and Femara ... - Cancer Consultants

Gleevec Has Activity for Treatment of Aggressive Fibromatosis  Mar 20, 2006
...mg/day). Thirteen of these patients had failed prior chemotherapy regimens usually containing anthracyclines and ifosfamide. They ... - Cancer Consultants



ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone ...  Feb 21, 2006
ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) presented preclinical data showing ZIO-201, the active metabolite of ifosfamide, may be less likely to kill normal ... - Genetic Engineering News,

ZIOPHARM Presents ZIO-201 Preclinical Kidney Toxicity Data at Bone ...  Feb 21, 2006
...(OTC BB: ZIOP) presented preclinical data showing ZIO-201, the active metabolite of ifosfamide, may be less likely to kill normal kidney cells than the other ... - PharmaLive.com,

Neoadjuvant Sarcoma Chemotherapy Results in High Toxicity Levels  Mar 1, 2006
The patients received three cycles of neoadjuvant modified mesna, doxorubicin, ifosfamide and dacarbazine (MAID), interdigitated radiotherapy and following ... - Cancerpage.com,

Neoadjuvant Chemotherapy and Radiotherapy Promising for Large Soft ...  Mar 3, 2006
All were scheduled to receive neoadjuvant concomitant radiotherapy and chemotherapy with MAID (mesna, ifosfamide, doxorubicin and dacarbazine). ... - Cancer Consultants,

ARIAD Initiates First Clinical Trial of Oral AP23573 in ...  Feb 14, 2006
The alkylating agent, ifosfamide, is often used in conjunction with doxorubicin in this clinical setting. Once the tolerability ... - Genetic Engineering News,

FDA Approves EMEND(R) (aprepitant), in Combination with Other ...  Jan 11, 2006
Chemotherapy agents that are known to be metabolized by CYP3A4 include docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine ... - Business Wire

Novel Strategies for Treating Lung Cancer: Chemotherapy  Jan 24, 2006
...mitomycin, vindesine, cisplatin) and BLT (Big Lung Trial from Great Britain) [9] using cisplatin combined with either vindesine, mitomycin, ifosfamide, or with ... - Medscape (subscription)

Cisplatin Benefits Patients with Metastatic Osteosarcoma  Jan 12, 2006
...treatment). The first trial assessed the chemotherapy drugs ifosfamide, cisplatin, doxorubicin, and high-dose methotrexate. The ... - Cancer Consultants

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional